ARGATROBAN
Generic: ARGATROBAN
Mylan Institutional LLCManufacturer
INTRAVENOUSRoute
ARGATROBANActive Substance
2014-06-30Original Approval
ARGATROBAN is FDA application ANDA202626, sponsored by MYLAN INSTITUTIONAL. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Top Reported Reactions
1
HEPARIN-INDUCED THROMBOCYTOPENIA
191 reports
2
DRUG INEFFECTIVE
157 reports
3
INTERNATIONAL NORMALISED RATIO INCREASED
110 reports
4
OFF LABEL USE
99 reports
5
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED
83 reports
6
HAEMORRHAGE
80 reports
7
PULMONARY EMBOLISM
70 reports
8
DEEP VEIN THROMBOSIS
69 reports
9
THROMBOCYTOPENIA
69 reports
10
COAGULATION TIME PROLONGED
64 reports